In last trading session, Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) saw 3.37 million shares changing hands with its beta currently measuring 0.56. Company’s recent per share price level of $0.77 trading at $0.05 or 7.66% at ring of the bell on the day assigns it a market valuation of $125.33M. That closing price of IRWD’s stock is at a discount of -997.4% from its 52-week high price of $8.45 and is indicating a premium of 23.38% from its 52-week low price of $0.59. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.3 million shares which gives us an average trading volume of 3.93 million if we extend that period to 3-months.
For Ironwood Pharmaceuticals Inc (IRWD), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.67. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.01 in the current quarter.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) trade information
Upright in the green during last session for gaining 7.66%, in the last five days IRWD remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $0.77 price level, adding 6.97% to its value on the day. Ironwood Pharmaceuticals Inc’s shares saw a change of -82.52% in year-to-date performance and have moved 7.24% in past 5-day. Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) showed a performance of -48.02% in past 30-days. Number of shares sold short was 11.25 million shares which calculate 3.87 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 4 to the stock, which implies a rise of 80.75% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -29.87% in reaching the projected high whereas dropping to the targeted low would mean a loss of -29.87% for stock’s current value.
Ironwood Pharmaceuticals Inc (IRWD) estimates and forecasts
This year revenue growth is estimated to fall -18.31% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 66.77M for the same. And 6 analysts are in estimates of company making revenue of 72.03M in the next quarter. Company posted 74.88M and 94.4M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -47.49% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 769.75% while estimates for its earnings growth in next 5 years are of 141.01%.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)’s Major holders
Insiders are in possession of 1.94% of company’s total shares while institution are holding 102.24 percent of that, with stock having share float percentage of 104.26%. Investors also watch the number of corporate investors in a company very closely, which is 102.24% institutions for Ironwood Pharmaceuticals Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at IRWD for having 22.88 million shares of worth $149.16 million. And as of 2024-06-30, it was holding 14.3868 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 21.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 13.5607 of outstanding shares, having a total worth of $140.59 million.
On the other hand, Pacer Funds Trust-Pacer US Small Cap Cash Cows ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 11.05 shares of worth $8.55 million or 6.83% of the total outstanding shares. The later fund manager was in possession of 4.19 shares on Dec 31, 2024 , making its stake of worth around $3.25 million in the company or a holder of 2.59% of company’s stock.
